Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexa B Schrock

Showing results (31-40 of 130) with videos related to

Pageof 13
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 29, 2020
Clinicopathologic Characteristics of BRG1-Deficient NSCLCIbiayi Dagogo-Jack, Alexa B Schrock, Marina Kem, et al.
Future Oncology (London, England)|August 31, 2021
Real-world association of HER2/<i>ERBB2</i> concordance with trastuzumab clinical benefit in advanced esophagogastric cancerStacey M Stein, Jeremy Snider, Siraj M Ali, et al.
JCO Precision Oncology|January 20, 2022
<i>ERBB2</i> Copy Number as a Quantitative Biomarker for Real-World Outcomes to Anti-Human Epidermal Growth Factor Receptor 2 Therapy in Advanced Gastroesophageal AdenocarcinomaLiangliang Zhang, Omar Hamdani, Ole Gjoerup, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 2, 2022
Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast CarcinomaHope S Rugo, Kira Raskina, Alexa B Schrock, et al.
NPJ Precision Oncology|January 23, 2023
Genomic landscape of 891 RET fusions detected across diverse solid tumor typesVamsi Parimi, Khaled Tolba, Natalie Danziger, et al.
Lung Cancer (Amsterdam, Netherlands)|August 22, 2020
Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profilingRussell Madison, Alexa B Schrock, Emily Castellanos, et al.
Lung Cancer (Amsterdam, Netherlands)|March 14, 2017
Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?Sai-Hong Ignatius Ou, Thomas K Lee, Lauren Young, et al.
JAMA Oncology|June 16, 2017
Genomic Profiling of Small-Bowel AdenocarcinomaAlexa B Schrock, Craig E Devoe, Robert McWilliams, et al.
JCO Precision Oncology|May 18, 2022
Clustered 8-Oxo-Guanine Mutations and Oncogenic Gene Fusions in Microsatellite-Unstable Colorectal CancerRussell W Madison, Xiaoju Hu, Vivek Ramanan, et al.
JCO Precision Oncology|September 3, 2021
Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment PatternsJessica K Lee, Russell Madison, Anthony Classon, et al.
Pageof 13

Showing results (31-40 of 130) with videos related to

Sort By:
Pageof 13
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 29, 2020
Clinicopathologic Characteristics of BRG1-Deficient NSCLCIbiayi Dagogo-Jack, Alexa B Schrock, Marina Kem, et al.
Future Oncology (London, England)|August 31, 2021
Real-world association of HER2/<i>ERBB2</i> concordance with trastuzumab clinical benefit in advanced esophagogastric cancerStacey M Stein, Jeremy Snider, Siraj M Ali, et al.
JCO Precision Oncology|January 20, 2022
<i>ERBB2</i> Copy Number as a Quantitative Biomarker for Real-World Outcomes to Anti-Human Epidermal Growth Factor Receptor 2 Therapy in Advanced Gastroesophageal AdenocarcinomaLiangliang Zhang, Omar Hamdani, Ole Gjoerup, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 2, 2022
Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast CarcinomaHope S Rugo, Kira Raskina, Alexa B Schrock, et al.
NPJ Precision Oncology|January 23, 2023
Genomic landscape of 891 RET fusions detected across diverse solid tumor typesVamsi Parimi, Khaled Tolba, Natalie Danziger, et al.
Lung Cancer (Amsterdam, Netherlands)|August 22, 2020
Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profilingRussell Madison, Alexa B Schrock, Emily Castellanos, et al.
Lung Cancer (Amsterdam, Netherlands)|March 14, 2017
Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?Sai-Hong Ignatius Ou, Thomas K Lee, Lauren Young, et al.
JAMA Oncology|June 16, 2017
Genomic Profiling of Small-Bowel AdenocarcinomaAlexa B Schrock, Craig E Devoe, Robert McWilliams, et al.
JCO Precision Oncology|May 18, 2022
Clustered 8-Oxo-Guanine Mutations and Oncogenic Gene Fusions in Microsatellite-Unstable Colorectal CancerRussell W Madison, Xiaoju Hu, Vivek Ramanan, et al.
JCO Precision Oncology|September 3, 2021
Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment PatternsJessica K Lee, Russell Madison, Anthony Classon, et al.
Pageof 13